You are here

Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Epilepsies
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3-15 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All the pediatric subjects (aged 3-15 years) whom an investigator prescribes the first
gabapentin (tablets, syrup, and switch to syrup from tablet) should be registered
consecutively until the number of subjects reaches target number in order to extract
patients enrolled into the investigation at random.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have been enrolled in the drug use investigation of Gabapen tablets in
adults (protocol No. A9451163).

- Patients who receive Gabapen tablets or syrup before, except for switched from tablets
to syrup.

NCT01441401
Pfizer
Completed
Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Partial Epilepsies
NCT00351611
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now